Biotech entity
Each story carries 8.8 original sources on average, compared with 3.4 for the broader beat in this window. Coverage clusters in fda-approval, which accounts for 13 of those 20, with the remainder spread across 3 other categories. Robert F. Kennedy Jr. is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories.
Last mentioned: Jul 16, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 45 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Each story carries 8.8 original sources on average, compared with 3.4 for the broader beat in this window. Coverage clusters in fda-approval, which accounts for 13 of those 20, with the remainder spread across 3 other categories. Robert F. Kennedy Jr. is the most frequent co-covered peer, appearing in 5 of the 20 tracked stories. The 47-day window averages about 3 stories each week. The busiest single day carried 3. Sentiment skews less negative than the wider beat, at 10% negative against 18% across all 245 Biotech stories in the same window. The 6.7 average consequence score is above the beat benchmark of 6 in the same window. We currently track 20 Biotech stories that mention FDA, published between July 12, 2026 and August 27, 2026.
Computed from the 20 stories linked to this entity, with beat comparisons drawn from all 245 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering FDA. Shared-story counts are live from our verified record — not editorial picks.
Strategic Target
Deadline for China to become the primary global exporter of medical technology standards.
Phase I Trials
Anticipated start of first-in-human safety and dosage escalation studies.
IND Filing
Target window for filing an Investigational New Drug application with the FDA.
Hybrid Submission Standards
Expected formalization of regulatory pathways that prioritize NAM data over animal data for specific drug classes.
Potential Launch
Anticipated commercial availability following regulatory approval and CDC recommendation.
Commercial Drug Delivery Readiness Target
ClearPoint aims to have its commercial infrastructure and installed base ready to support partner drug launches.
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Pre-clinical Completion
Expected conclusion of animal model testing and toxicology reports.
First Approvals
Anticipated first wave of gene therapy approvals under the new streamlined framework.
APOLLO Trial Data
Expected top-line results from the Phase 2/3 APOLLO trial in Q4 2026.
Regulatory Filing
Expected submission of Biologics License Application (BLA) to the FDA.
Trump announces Heidi Overton as FDA Commissioner nominee
President Trump names the White House Domestic Policy Council deputy director to lead the FDA, pending Senate confirmation.
Moderna flu vaccine PDUFA date
FDA target decision deadline for Moderna's mRNA-based seasonal influenza vaccine.
FDA Decision Deadline
The agency faces a deadline to approve or reject the vaccine.
FDA Approval of mRNA-1010
The FDA approved Moderna's mRNA flu vaccine for adults 50+, with traditional approval for ages 50–64 and accelerated approval for ages 65+.
Q2 2026 Earnings Release
ClearPoint Neuro announces quarterly results and highlights FDA guidance reversal and commercial restructuring.
PCAC Votes to Recommend Six Peptides
The committee votes to recommend BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax for inclusion on the 503A Bulks List, culminating the multi-day review.
Clarification on US Primary Endpoint
Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
FDA PCAC Public Meeting Begins
The Pharmacy Compounding Advisory Committee commences a two-day meeting to review nominations of bulk drug substances, including six peptide candidates, for the 503A Bulks List.
FDA Approves Lipfendra
The FDA approved Lipfendra (enlicitide), the first once-daily oral PCSK9 inhibitor, for adults with hypercholesterolemia including inherited forms, based on Phase 3 CORALreef trials showing 56-59% LDL-C reduction.
For biotech and pharma professionals, Revolution Medicines' daraxonrasib becomes the first approved multi-RAS inhibitor, with Phase 3 median overall survival of 13.2 months vs 6.6 on chemo, validating the RAS(ON) platform and opening a new commercial front in pancreatic cancer.
Source: ABCNews (US) · Madeline Halpert (gb)
Neridronate, an investigational CRPS-1 bisphosphonate already approved in Italy, moves into a 270-patient pivotal CRPS-RISE Phase 3 with FDA Breakthrough, Fast Track, and Orphan designations. The all-stock Werewolf-Ambros merger and oversubscribed $150 million private placement fund development through topline in 2028.
Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Source: edition.cnn.com · freerepublic.com
For biotech and pharma executives, Overton's nomination combines Trump's favored-nation drug pricing push with RFK Jr.'s vaccine skepticism and unfinished reviews of antidepressants and COVID shots. The result could compress margins while opening faster approval pathways for innovation. Investors should watch how she navigates evidence standards and political priorities at the FDA.
Source: MedPage Today · Kstp Television
Moderna's mRNA flu vaccine mRNA-1010 secures FDA approval, showing a 27.4% relative efficacy advantage over standard-dose in adults 65+, validating mRNA technology for seasonal influenza.
Source: livescience.com · MedPage Today
The biotech’s mRNA influenza vaccine, mFLUSIVA, gained FDA approval for the 50+ demographic based on a 40,000-subject safety and immunogenicity study that indicated stronger protection versus traditional shots. The nod validates Moderna’s platform beyond COVID-19 and opens a new commercial front in the competitive flu vaccine market.
Source: kawc.org · wknofm.org
ClearPoint Neuro's Q2 biologics revenue fell 15% as clinical trial product shipments slowed, but the newly operational CAL facility and an FDA regulatory pivot on rare diseases are expected to re-ignite growth in the cell and gene therapy delivery segment.
Source: theusnews.com · albuquerqueexpress.com
Median Technologies’ eyonis LCS, an AI diagnostic for lung nodule malignancy, secures a commercial partner in Canon’s Olea Medical, potentially accelerating adoption of precision screening and impacting early-stage cancer treatment paradigms.
Despite FDA scientists’ safety concerns, an advisory panel overwhelmingly backed six peptide therapies for compounding, including TB-500 and MOTS-c. The biotech sector watches closely as the FDA prepares for rulemaking, which may redefine the boundary between pharmaceutical development and pharmacy compounding.
Source: wknofm.org · wmuk.org
After a shocking FDA refusal-to-file in February and a subsequent advisory panel endorsement, Moderna's experimental mRNA influenza vaccine faces a final decision on August 5. The outcome holds deep implications for the viability of mRNA technology beyond COVID-19 and the future of Moderna's pipeline diversification.
Source: news.wjct.org · wdiy.org
An FDA advisory committee endorsed six peptide substances for the 503A Bulks List, a milestone that could validate the therapeutic potential of BPC-157, TB-500, MOTS-c and others. Vanta is leveraging this to build a biotech platform combining peptide manufacturing with its consumer health portfolio.
The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Source: finanznachrichten.de · stockhouse.com
A divided FDA panel backed three unapproved peptides for pharmacy compounding despite agency warnings of insufficient safety data. The vote raises concerns about political influence and the erosion of evidence-based standards in biopharmaceutical regulation.
Source: nbcdfw.com · nbcnewyork.com
Biopharma companies watch as the Safe Drugs Act proposes to force large compounding pharmacies under FDA manufacturing standards, potentially curtailing compounded GLP‑1 copies that have capitalized on brand‑name shortages. The regulatory shift could favor innovators like Novo Nordisk and Eli Lilly, reshape the competitive landscape, and alter the risk‑reward calculus for obesity‑focused pipelines.
Source: vtcng.com · sanfordherald.com
The p-tau217 blood test’s ability to identify cognitively healthy adults with up to 78% ten-year risk of cognitive decline offers pharma a powerful tool to enrich Alzheimer prevention trials, potentially accelerating drug development and reducing costs.
Source: medicalnewstoday.com · irishdentist.ie
The first U.S. participant has been treated in MEDIPOST's Phase III trial of its allogeneic umbilical cord blood-derived MSC therapy for knee OA. The FDA agreed that this single pivotal study, supported by prior ex-U.S. Phase 3 data, may suffice for a BLA, positioning MEDIPOST at the forefront of regenerative medicine for osteoarthritis.
Source: philippinetimes.com
Laplace Interventional has obtained FDA IDE approval for its TRIUMPH pivotal trial, targeting 400 patients across 75 sites to test its transcatheter tricuspid valve replacement device. The study includes a 2:1 randomization against commercial TTVR and a 150-patient registry for harder-to-treat patients. Top U.S. cardiologists will lead the trial, building on promising early feasibility data.
Source: prnewswire.com · newswise.com
Merck won FDA approval for Lipfendra, a small-molecule oral PCSK9 inhibitor that achieved 56-59% LDL-C reductions in Phase 3. This breakthrough in oral delivery challenges the dominance of injectable biologics from Amgen and Sanofi/Regeneron.
Source: mix969.iheart.com · rock1053.iheart.com
Biotech venture capital surged to $9.1 billion in the first half of 2026, yet the majority flowed to companies with drugs already in clinical testing, leaving preclinical-stage firms facing a severe funding drought. This divergence threatens the future drug pipeline even as IPO and M&A markets boom.
Source: Gwendolyn Wu · BioPharma Dive
FDA’s acceptance of existing clinical data for uniQure’s AMT-130 gene therapy signals a major regulatory win, with the company on track for a BLA submission in Q3 2026 and a potential first-in-class approval for Huntington’s disease.
FDA is linked from 87 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
